A community from npj Precision Oncology

Behind the paper

Share the story behind your paper, from conception to publication, the highs and the lows

AP-1/Fos function in prostate cancer; An in vivo CRISPR/Cas9 approach

Contributor Oncogene

Behind the paper

Cas9 approach

Martin K. Thomsen and 1 other

Mar 08, 2021

A novel therapeutic approach to MYC-driven cancer

Contributor Oncogene

Behind the paper

A novel therapeutic approach to MYC-driven cancer

Belamy Cheung

Mar 05, 2021

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.

Contributor npj Precision Oncol

Behind the paper

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.

Mauricio Ribeiro

Mar 04, 2021

Contributor BJC

Behind the paper

Circulating tumor DNA as a practical diagnostic tool for post-treatment monitoring

Satoshi Nishizuka

Mar 03, 2021

Short Histone H2A Variants are Expressed in Cancer

Contributor Nature Comms

Behind the paper

Short Histone H2A Variants are Expressed in Cancer

Jay Sarthy and 1 other

Mar 03, 2021

The ins and outs of nuclear β-arrestin2 on Mdm2-p53 signalling

Contributor Oncogene

Behind the paper

The ins and outs of nuclear β-arrestin2 on Mdm2-p53 signalling

Mark Scott and 2 others

Mar 01, 2021

Retroviral integrations contribute to elevated host cancer rates during germline invasion

Contributor Nature Comms

Behind the paper

Retroviral integrations contribute to elevated host cancer rates during germline invasion

Gayle McEwen and 1 other

Feb 26, 2021

Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis

Contributor npj Precision Oncol

Behind the paper

Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis

Chiara Carretta and 4 others

Feb 25, 2021

Combating CLL Drug Resistance

Contributor Blood Cancer

Behind the paper

Combating CLL Drug Resistance

Dr. Sutapa Sinha and 1 other

Feb 24, 2021

Understanding the immune responses in angiosarcomas and their clinical implications

Contributor npj Precision Oncol

Behind the paper

Understanding the immune responses in angiosarcomas and their clinical implications

Jason Yongsheng Chan and 1 other

Feb 24, 2021

Non-steroidal anti-inflammatory drugs induce immunogenic cell death in suppressing colorectal tumorigenesis

Contributor Oncogene

Behind the paper

Non-steroidal anti-inflammatory drugs induce immunogenic cell death in suppressing colorectal tumorigenesis

Rochelle Fletcher and 1 other

Feb 24, 2021

Esterase enzymes in multiple myeloma: enablers of effective treatments, biomarkers of progression, or both?

Contributor

Behind the paper

Esterase enzymes in multiple myeloma: enablers of effective treatments, biomarkers of progression, or both?

Caroline Heckman

Feb 23, 2021

Unveiling mechanisms of resistance to immunotherapy: Tumor intrinsic JAK2 downmodulation leads to IFN-gamma deficient response and acquired resistance to T cell redirection therapies

Contributor Nature Comms

Behind the paper

Unveiling mechanisms of resistance to immunotherapy: Tumor intrinsic JAK2 downmodulation leads to IFN-gamma deficient response and acquired resistance to T cell redirection therapies

Enrique Javier Arenas Lahuerta and 2 others

Feb 23, 2021

Proteasome tyrosine phosphorylation at the membrane

Contributor Oncogene

Behind the paper

Proteasome tyrosine phosphorylation at the membrane

Xing Guo

Feb 20, 2021

Differentiating HER2-targeted tyrosine kinase inhibitors

Contributor BJC

Behind the paper

Differentiating HER2-targeted tyrosine kinase inhibitors

Neil Conlon

Feb 19, 2021

Comorbidity in chronic lymphocytic leukemia

Contributor Leukemia

Behind the paper

Comorbidity in chronic lymphocytic leukemia

Emelie Curovic Rotbain and 2 others

Feb 18, 2021

Unveil mysterious “super-enhancers” in multiple myeloma

Contributor Blood Cancer

Behind the paper

Unveil mysterious “super-enhancers” in multiple myeloma

Wee Joo Chng and 1 other

Feb 18, 2021

Contributor Blood Cancer

Behind the paper

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes

Konstantinos Liapis & Ioannis Kotsianidis, on behalf of the Hellenic National Registry of Myelodysplastic and Hypoplastic Syndromes.

Konstantinos Liapis

Feb 14, 2021

Contributor Nature Comms

Behind the paper

The Acquisition of Molecular Drivers in Pediatric Therapy-Related Myeloid Neoplasms

Jason Schwartz

Feb 12, 2021

Mass spectrometry is a highly sensitive peripheral blood marker for measurable residual disease in multiple myeloma

Contributor Blood Cancer

Behind the paper

Mass spectrometry is a highly sensitive peripheral blood marker for measurable residual disease in multiple myeloma

Ben Derman and 2 others

Feb 11, 2021

Nature Portfolio Cancer Community

Behind the paper

AP-1/Fos function in prostate cancer; An in vivo CRISPR/Cas9 approach

A novel therapeutic approach to MYC-driven cancer

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.

Circulating tumor DNA as a practical diagnostic tool for post-treatment monitoring

Short Histone H2A Variants are Expressed in Cancer

The ins and outs of nuclear β-arrestin2 on Mdm2-p53 signalling

Retroviral integrations contribute to elevated host cancer rates during germline invasion

Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis

Combating CLL Drug Resistance

Understanding the immune responses in angiosarcomas and their clinical implications

Non-steroidal anti-inflammatory drugs induce immunogenic cell death in suppressing colorectal tumorigenesis

Esterase enzymes in multiple myeloma: enablers of effective treatments, biomarkers of progression, or both?

Unveiling mechanisms of resistance to immunotherapy: Tumor intrinsic JAK2 downmodulation leads to IFN-gamma deficient response and acquired resistance to T cell redirection therapies

Proteasome tyrosine phosphorylation at the membrane

Differentiating HER2-targeted tyrosine kinase inhibitors

Comorbidity in chronic lymphocytic leukemia

Unveil mysterious “super-enhancers” in multiple myeloma

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes

The Acquisition of Molecular Drivers in Pediatric Therapy-Related Myeloid Neoplasms

Mass spectrometry is a highly sensitive peripheral blood marker for measurable residual disease in multiple myeloma

Register to Nature Portfolio Cancer Community